Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain

NCT00399659 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00399659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00399659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2006
Completion date
April 30, 2007
Enrollment
360 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

opioid-induced constipation